This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Quarter loss and 33% half-year revenue decline
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 4.1 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved standalone unaudited results for the quarter and six months ended 30 September 2026. Six-month revenue fell to Rs 1.80 million from Rs 2.68 million, while net loss was Rs 51,569 versus profit of Rs 279,580. In Q2, revenue was Rs 380,000, unchanged year on year, but the company posted a Rs 197,731 loss. Operating cash flow was positive Rs 192,750. The auditor's limited review found no material misstatement.
Lower sales and a shift to loss may pressure the share price, though positive operating cash flow and a clean limited review offer some support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.09 Cr | −100.0% |
| Operating profit | −₹0.02 Cr | ₹0.00 Cr | −700.0% |
| Profit after tax | −₹0.02 Cr | ₹0.00 Cr | −700.0% |
| EBITDA margin | — | 4.6% | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.